A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients

<table>PRDFS rates and exact 95% confidence intervals after 12 months of treatment with<i> Viscum</i> or Etoposide, respectively. The horizontal line represents the 12% PRDFS rate derived from historical controls. By crossing the 12% line, the Etoposide confidence interval indicates that this treatment cannot statistically be distinguished from the historical rate, whereas for<i> Viscum</i> a significant difference can be deduced.</table>

Evidence-Based Complementary and Alternative Medicine

fig1

Figure 1

Figure 1: A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients 